#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Distribúcia HIV-1 subtypov a rezistencie na ART u HIV-infikovaných osôb na Slovensku (2019–2021)


Autoři: A. Kovářová 1,2;  D. Valkovičová Staneková 2 ;  M. Hábeková 2 ;  M. Takáčová 2
Působiště autorů: Department of Laboratory Investigation Methods in Healthcare, Faculty of Health Sciences and Social Work, The University of Trnava, Trnava, Slovak Republica 1;  National Reference Centre for HIV/AIDS Prevention, Slovak Medical University, Bratislava, Slovak Republic 2
Vyšlo v časopise: Epidemiol. Mikrobiol. Imunol. 72, 2023, č. 4, s. 203-212
Kategorie: Původní práce

Souhrn

Cieľ: Cieľom štúdie bolo popísať výskyt HIV-1 subtypov a HIV-1 kmeňov rezistentných na antiretrovírusovú liečbu (ART) u HIV pozitívnych osôb novo diagnostikovaných na Slovensku v rokoch 2019–2021.

Materiál a metódy: Študijnú skupinu tvorilo 184 HIV pozitívnych naivných pacientov novo diagnostikovaných na Slovensku v rokoch 2019–2021. Vírusová HIV-1 RNA bola izolovaná z plazmy pomocou QIAamp Viral RNA Mini Kit (QIAGEN, Nemecko). Pre RT-PCR a sekvenovanie oblasti HIV pol sme použili interné postupy podľa protokolu ANRS AC11 pre RT (reverzná transkriptáza), PRO (proteáza) a IN (integráza) (ANRS AC11 Resistance Study Group, 2015). Analýzu sekvencií sme uskutočnili pomocou softvéru Sequencing Analysis Software v5.3 (Applied Biosystems®). HIV sekvencie boli manuálne upravené pomocou BioEdit (verzia 7.2.5), porovnané s konsenzuálnymi HIV-1 sekvenciami v Los Alamos Sequence Database (URL 2), zarovnané pomocou CLUSTAL W (Labarga et al., 2007) a softvérových balíkov BioEdit (verzia 7.2 .5) (Hall, 1999). Na vyhodnotenie sekvencie sme použili algoritmus HIVDB (verzia 9.0) Stanfordskej databázy HIV liekovej rezistencie (URL 1.). Na analýzu HIV-1 subtypov sme použili nástroj REGA HIV-1 Subtyping Tool (De Oliviera et al., 2005) a fylogenetickú analýzu sme vypracovali pomocou programu MEGA X (Kumar et al., 2018).

Výsledky: Fylogenetickú analýzu sme vykonali zo vzoriek 184 osôb, kde sme odhalili najrozšírenejší subtyp B (129/184, 70,11 %) prevládajúci v populácii u mužov, ktorí majú sex s mužmi (MSM) (96/129 74,42 %). Čo sa týka non-B subtypov (55/184, 29,89 %), najrozšírenejší bol subtyp A (48/184, 26,09 %) v porovnaní so subtypom F (F1) (3; 1,63 %), C (1; 0,54 %) a cirkulujúcimi rekombinantnými formami CRF02_AG (2; 1,09 %), CRF01_AE (1; 0,54 %). U 9,24 % (17/184) vzoriek sme zistili prítomnosť 25 mutácií asociovaných s HIV rezistenciou na ART, z toho 7,07 % (13/184) na inhibítory reverznej transkriptázy, 1,66 % (3/181) na inhibítory proteázy a 1,32 % (2/151) na inhibítory integrázy. Okrem toho u 1,63 % (3/184) pacientov bola prítomná viactriedna rezistencia. Mutácie asociované s rezistenciou HIV na ART sa našli u 9,30 % osôb infikovaných podtypom B.

Záver: Naša štúdia potvrdila pretrvávajúci najvyšší výskyt subtypu B s mierne klesajúcou tendenciou v porovnaní s minulými rokmi. Detekcia mutácií vytvárajúcich rezistenciu HIV na ART podčiarkuje potrebu testovania rezistencie u naivných pacientov ešte pred začatím ART na Slovensku.


Zdroje
  1. Abram ME, Ferris AL, Shao W, et al. Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J Virol, 2010;84(19):9864–9878.
  2. Alaeus A. Significance of HIV-1 genetic subtypes. Scand J Infect Dis, 2000;32(5):455–463.
  3. Alexiev I, Campbell EM, Knyazev S, et al. Molecular Epidemiology of the HIV-1 Subtype B Sub-Epidemic in Bulgaria. Viruses, 2020;12(4):441.
  4. ANRS AC11 Resistance Study Group (2015): PCR and sequencing procedures: HIV-1 [online]. Version January 2015 [cit. 2023-0206]. Available at www: https://hivfrenchresistance.org/wp-content/uploads/2021/10/ANRS-procedures.pdf
  5. Asante-Appiah E, Lai J, Wan H, et al. Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates. Antimicrob Agents Chemother, 2021; 65(12):e01216–1221.
  6. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother, 2010;54(2):718–727.
  7. Beloukas A, Psarris A, Giannelou P, et al. Molecular epidemiology of HIV-1 infection in Europe: An overview. Inf Gen Evol, 2016;46 : 180–189.
  8. Cuevas JM, Geller R, Garijo R, et al. Extremely High Mutation Rate of HIV-1 In Vivo. PLoS Biol, 2015;13(9):1002251.
  9. Čereš A, Staneková D, Hábeková M, et al. 2018. HIV genetic diversity and occurrence of the HLA-B*57 : 01 allele in newly diagnosed HIV-positive patients in Slovakia in 2015–2016. Clinical Microbiology Reports. pp. 39, EV 2992/09, Year XVIII., Number SA/2018. ISSN 1338–645X.
  10. Davanos N, Panos G, Gogos Ch, Mouzaki A. HIV-1 subtype characteristics of infected persons living in southwestern Greece. HIV AIDS (Auckl), 2015;7 : 277–283.
  11. Delgado E, Benito S, Montero V, et al. Diverse Large HIV-1 Non-subtype B Clusters Are Spreading Among Men Who Have Sex With Men in Spain. Front Microbiol, 2019;10.
  12. De Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics, 2005;21(19):3797–3800.
  13. Felsenstein J. Confidence limits on phylogenies: An approach using the bootstrap. Evolution, 1985;39(4):783–791.
  14. Feng M, Wang D, Grobler JA, et al. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother, 2015;59(1):590–598.
  15. Hall T. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser, 1999;41 : 95–98.
  16. Hauser A, Hofmann A, Meixenberger K, et al. Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses. PLoS ONE, 2018;13(11):e0206234.
  17. Hábeková M, Kovářová A, Takáčová M, Valkovičová Staneková D. Distribution of subtypes HIV1 in Slovakia: update 2017 –⁠ 2018. Acta Virol, 2023. ISSN 0001–723X.
  18. Hábeková M, Takáčová M, Lysy J, et al. Genetic Subtypes of HIV Type 1 Circulating in Slovakia. AIDS Research and Human Retroviruses, 2010;26(10):1103–1107.
  19. Hemelaar J, Elangovan R, Yun J, et al. Global and regional molecular epidemiology of HIV-1, 1990–2015: A systematic review, global survey, and trend analysis. Lancet Infect Dis, 2019;19 : 143 –⁠ 155.
  20. Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends Mol Med, 2012;18(3):182–192.
  21. Hofstra LM, Sauvageot N, Albert J, et al. Ryding, for the SPREAD Program, Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. Clin Infect Dis, 2016;62(5):655–663.
  22. Hofstra LM, Seguin-Devaux C, Struck D, et al. The prevalence of drug resistance mutations in newly-diagnosed HIV-patients in Europe: interactive monitoring. In: Hofstra M. HIV Drug Resistance. Utrecht: University of Utrecht; 2019. pp. 63–77. ISBN: 978-94-6361-225-8
  23. Chabadová Z, Habeková M, Truska P, et al. Distribution of HIV-1 subtypes circulating in Slovakia (2009–2012). Acta Virol, 2014;58(4):317–324.
  24. Junqueira DM, de Matos Almeida SE. HIV-1 subtype B: Traces of a pandemic. Virology, 2016;495 : 173–184.
  25. Kimura M. A simple method for estimating evolutionary rate of base substitutions through comparative studies of nucleotide sequences. J Mol Evol, 1980;16(2):111–120.
  26. Klundert MAA, Antonova A, Di Teodoro G et al. Molecular Epidemiology of HIV-1 in Eastern Europe and Russia. Viruses, 2022;14(10):2099.
  27. Konstantinos A, Albert J, Mamais I, et al. Global dispersal pattern of HIV-1 CRF01_AE: A genetic trace of human mobility related to heterosexual activities centralized in South-East Asia J Infect Dis, 2015;211 : 1735–1744.
  28. Kostaki EG, Limnaios S, Adamis G, et al. Estimation of the determinants for HIV late presentation using the traditional definition and molecular clock-inferred dates: Evidence that older age, heterosexual risk group and more recent diagnosis are prognostic factors. HIV Medicine, 2022;23(11):1143–1152.
  29. Kumar S, Stecher G, Li M, et al. MEGA X: Molecular Evolutionary Genetics Analysis across computing platforms. Mol Biol Evol, 2018;35(6):1547–1549.
  30. Labarga A, Valentin F, Anderson M, Lopez R. Web services at the European bioinformatics institute. Nucleic Acids Res, 2007; 35(Web Server issue): W6–W11.
  31. Lai MT, Feng M, Falgueyret JP, et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother, 2014;58(3):1652–1663.
  32. Lee HY, Perelson AS, Park SC, Leitner T. Dynamic correlation between intrahost HIV-1 quasispecies evolution and disease progression. PLoS Comput Biol, 2008;4(12):e1000240.
  33. Lorenzin G, Gargiulo F, Caruso A, et al. Prevalence of Non-B HIV-1 Subtypes in North Italy and Analysis of Transmission Clusters Based on Sequence Data Analysis. Microorganisms, 2020;8(1):36.
  34. Lunar MM, Vandamme AM, Tomažič J, et al. Bridging epidemiology with population genetics in a low incidence MSM-driven HIV-1 subtype B epidemic in Central Europe. BMC Infect Dis, 2015;15 : 65.
  35. Magiorkinis G, Angelis K, Mamais I, et al. The global spread of HIV-1 subtype B epidemic. Infect Genet Evol, 2016;46 : 169–179.
  36. Matuzzi L, Melengu T, Falasca F, et al. Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naïve patients: A single-centre experience. J Glob Antimicrob Resist, 2020;20 : 298–303.
  37. Melikian GL, Rhee SY, Varghese V, et al. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother, 2014;69(1):12–20.
  38. Mravčík V, Pitoňák M, Hejzák R, et al. HIV epidemic among men who have sex with men in the Czech Republic, 2016: high time for targeted action. Euro Surveill. 2017;22(48):17–00079.
  39. Murillo W, Veras NMC, Prosperi MCF, et al. A single early introduction of HIV-1 subtype B into Central America accounts for most current cases. J Virol, 2013;87 : 7463–7470.
  40. Mustafa A, Akbay B, Davlidova S, et al. Origin and evolution of subtype B variants in the former Soviet Union countries. Infect Genet Evol, 2023;108 : 105402.
  41. Neogi U, Häggblom A, Santacatterina M, et al. Temporal Trends in the Swedish HIV-1 Epidemic: Increase in Non-B Subtypes and Recombinant Forms over Three Decades. PLoS ONE, 2014;9(6):e99390.
  42. Oroz M, Begovac J, Planinić A, et al. Analysis of HIV-1 diversity, primary drug resistance and transmission networks in Croatia. Sci Rep, 2019;9(1):17307.
  43. Paraskevis D, Nikolopoulos GK, Magiorkinis G, et al. The application of HIV molecular epidemiology to public health. Infect Genet Evol, 2016;46 : 159–168.
  44. Parczewski M, Leszczyszyn-Pynka M, Witak-Jedra M, et al. Distribution and time trends of HIV-1 variants in Poland: Characteristics of non-B clades and recombinant viruses. Infect Genet Evol, 2016;39 : 232–240.
  45. Pingarilho M, Pimentel V, Miranda MNS, et al. HIV-1-Transmitted Drug Resistance and Transmission Clusters in Newly Diagnosed Patients in Portugal Between 2014 and 2019. Front Microbiol, 2022;13 : 823208.
  46. Public Health Authority of the Slovak Republic. Incidence of infection in the Slovak Republic until June 30, 2022 [online]. 2022 [cit. 2023-02-01]. Available at www: <https:// www.uvzsr.sk/index.php?option=com_content&view=ar- ticle&id=5463%3Avyskyt-hiv-infekcie-v-slovenskej-repub like-k-306-2022&catid=283%3Ahivaids&Itemid=112>.
  47. Rhee SY, Grant PM, Tzou PL, et al. A systematic review of the genetic mechanisms of dolutegravir resistance. J Antimicrob Chemother, 2019;74(11):3135–3149.
  48. Rhee SY, Parkin N, Harrigan PR, et al. Genotypic Correlates of Resistance to the HIV-1 Strand Transfer Integrase Inhibitor Cabotegravir. Review 2022 Sept. 01, PREPRINT (Version 1). Available at www: https://doi.org/10.21203/rs.3.rs-2012078/v1.
  49. Rhee SY, Schapiro JM, Saladini F, et al. Potential Role of Doravirine for the Treatment of Patients with Transmitted Drug Resistance. AIDS Res Ther, 2023;20 : 8.
  50. Rimsky L, Vingerhoets J, Van Eygen V, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr, 2012 Jan 1;59(1):39–46.
  51. Rizzardini G, Overton ET, Orkin C, et al. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. J Acquir Immune Defic Syndr, 2020;85(4):498–506.
  52. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol, 1987;4(4):406 –⁠ 425.
  53. Serwin K, Scheibe K, Horecki M, et al. Detection of Polish cases of highly virulent subtype B of HIV-1 originating in the Netherlands. Journal of Medical Virology, 2022;95(1):28154.
  54. Serwin K, Urbańska A, Scheibe K, et al. Molecular epidemiology and HIV-1 variant evolution in Poland between 2015 and 2019. Sci Rep, 2021;11 : 16609.
  55. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med, 2011;1(1):a006841.
  56. Tambuyzer L, Nijs S, Daems B, et al. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptbility and virologic response to etravirine. J Acquir Immune Defic Syndr, 2011;58(1):18–22.
  57. Tsiang M, Jones GS, Goldsmith J, et al. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob Agents Chemother, 2016;60(12):7086–7097.
  58. UNAIDS. Global HIV & AIDS statistics –⁠ Fact sheet [online]. 2023 [cit. 2023-02-03]. Available at www: <https://www.unaids.org/ en/resources/fact-sheet>.
  59. URL 1. STANFORD HIVDB PROGRAM. Release notes [online]. 2021 [cit. 2023-02-04]. Available at www: <https://hivdb.stanford.edu/page/release-notes/>.
  60. URL 2. NRTI Resistance Notes [online]. 2022 [cit. 2023-02-04]. Available at www: <https://hivdb.stanford.edu/dr-summary/ resistance-notes/NRTI/>.
  61. URL 3. PI Resistance Notes [online]. 2022 [cit. 2023-02-04]. Available at www: <https://hivdb.stanford.edu/dr-summary/resistance-notes/PI/>.
  62. URL. 4. HIV sequence database [online]. 2019 [cit. 2023-0119]. Available at www: <https://www.hiv.lanl.gov/content/se- quence/LOCATE/locate.html>.
  63. Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS, 2010;24(4):503–514.
  64. Mortier V, Debaisieux L, Dessilly G, et al. Prevalence and Evolution of Transmitted Human Immunodeficiency Virus Drug Resistance in Belgium Between 2013 and 2019. Open Forum Infect Dis, 2022;9(7):195.
  65. Westen GJP, Hendriks A, Wegner JK, et al. Significantly improved HIV inhibitor efficacy prediction employing proteochemometric models generated from antivirogram data. PLoS Comput Biol, 2013. Available at www: https://doi.org/10.1371/journal. pcbi.1002899.
  66. WHO. HIV [online]. 2022 [cit. 2023-02-04]. Available at www:<https://www.who.int/news-room/fact-sheets/detail/hiv-  aids>.
  67. Wymant CH, Bezemer D, Blanquart F, et al. A highly virulent variant of HIV-1 circulating in the Netherlands. Science, 2022;375(6580):540–545.
  68. Yamaguchi J, McArthur C, Sthreshley L, et al. Brief Report: Complete genome sequence of CG-0018a-01 establishes HIV-1 subtype L. J Acquir Immune Defic Syndr, 2020;83(3):319–322.
Štítky
Hygiena a epidemiologie Infekční lékařství Mikrobiologie

Článek vyšel v časopise

Epidemiologie, mikrobiologie, imunologie

Číslo 4

2023 Číslo 4
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Mepolizumab v reálné klinické praxi kurz
Mepolizumab v reálné klinické praxi
nový kurz
Autoři: MUDr. Eva Voláková, Ph.D.

BONE ACADEMY 2025
Autoři: prof. MUDr. Pavel Horák, CSc., doc. MUDr. Ludmila Brunerová, Ph.D., doc. MUDr. Václav Vyskočil, Ph.D., prim. MUDr. Richard Pikner, Ph.D., MUDr. Olga Růžičková, MUDr. Jan Rosa, prof. MUDr. Vladimír Palička, CSc., Dr.h.c.

Cesta pacienta nejen s SMA do nervosvalového centra
Autoři: MUDr. Jana Junkerová, MUDr. Lenka Juříková

Svět praktické medicíny 2/2025 (znalostní test z časopisu)

Eozinofilní zánět a remodelace
Autoři: MUDr. Lucie Heribanová

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#